trial

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

NCTId NCT00161031
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 30 (estimated)
Sponsored by University of Maryland, Baltimore County
Primary completion 2006-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
30 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-04
Primary completion
2006-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
atomoxetine

Sponsors

University of Maryland, Baltimore CountyLead Sponsor

Investigators

1
Deanna L Kelly, Pharm.D.Principal Investigator

Sites

2 total
Baltimore, United StatesCatonsville, United States

Facts & assertions

4 sourced
Enrollment
30
Phase
NA
Primary Completion Date
2006-12
Status
COMPLETED
relationships
The graph out of here
drug
atomoxetine
drug
lead_sponsor
University of Maryland, Baltimore County
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Deanna L Kelly, Pharm.D.
person